MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount ...

MannKind (MNKD) delivered earnings and revenue surprises of -900.00% and +15.68%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

If you are wondering whether MannKind's current share price reflects its true worth, you are not alone. The stock screens quite differently depending on which valuation lens you use. MannKind's share ...

Shares of Mannkind (NASDAQ:MNKD) rose 7% in post-market trading Wednesday after the company issued its Q4 earnings report and a business update. Mannkind (NASDAQ:MNKD) reported a Q4 net profit of ...

MannKind (NASDAQ:MNKD) will reduce its outstanding debt by $194M following exchange of convertible notes for stock and cash. The company entered into separate, privately negotiated exchange agreements ...

MannKind (NASDAQ:MNKD) reaches a 1-year low, with its performance in Nasdaq Futures influencing broader biopharma market trends.

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind (MNKD) is a stock that can certainly grab the attention ...